Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome

Ann Rheum Dis. 2013 May;72(5):782-3. doi: 10.1136/annrheumdis-2012-202754. Epub 2012 Dec 21.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Interleukin-22
  • Interleukins / immunology
  • Interleukins / metabolism*
  • Male
  • Middle Aged
  • Rituximab
  • Salivary Glands / drug effects*
  • Salivary Glands / immunology
  • Salivary Glands / metabolism
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / immunology
  • Sjogren's Syndrome / metabolism
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Interleukins
  • Rituximab